In her husband's nearly 15 years of living with ALS, columnist Kristin Neva sees pre- and post-diagnosis papers as a bittersweet treasure.

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

The number of ALS cases in the U.S. is expected to increase by over 10% by 2030, as compared with 2022 prevalence rates, per ...

Neurosense entered a binding term sheet with a global pharmaceutical company to advance development and commercialization of ...

This content is sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA) and is intended for US audiences only. Any other ...

A Phase 1 trial testing RAG-17, a potential ALS therapy for people carrying SOD1 mutations, has dosed its first participant.

The creatinine-to-cystatin C ratio may indicate the risk of developing amyotrophic lateral sclerosis, a large-scale database ...

News stories about clinical trials testing potential treatments were among the top 10 most-read articles on ALS News Today in ...

After columnist Dagmar Munn was diagnosed with ALS, she began setting an intention for the new year instead of formal resolutions.

Despite the lower ALS risk, heart and metabolism problems are tied to faster disease progression and worse survival in the ...

Neurosense Therapeutics is working on finishing touches for the protocol of a Phase 3 study testing PrimeC, an oral treatment the company is developing for amyotrophic lateral sclerosis (ALS), and ...

People with diabetes or high cholesterol may be less likely to develop amyotrophic lateral sclerosis (ALS) or other motor neuron diseases (MNDs), but heart and metabolism problems are linked with ...